- ST. LOUIS, MO and SAN DIEGO, CA, November 9, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present new data highlighting the preclinical development of Wugen’s lead product WU-NK-101 at the Society for Immunotherapy of Cancer’s (SITC) 36thAnnual Meeting.
The data highlight Wugen’s proprietary large-scale feeder-cell free manufacturing process and demonstrate WU-NK-101’s robust memory phenotype and enhanced anti-tumor activity. Further, the data demonstrate that in combination with monoclonal antibodies, WU-NK-101 exhibits enhanced efficacy against solid tumor cell lines. In summary, the data provide support for development of WU-NK-101 as an off-the-shelf cell therapy for the treatment of acute myelogenous leukemia (AML) and solid tumors.
The details of Wugen’s presentation at SITC are as follows:
Title: Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity
Presenting Author: Mary E. Mathyer, Ph.D.
Abstract Number: 188
Abstracts will be available Tuesday, November 9, 2021, at 8:00 a.m. ET
Additional meeting information can be found on the SITC website at:
https://www.sitcancer.org/2021/home.
About Wugen
Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in clinical development for acute myelogenous leukemia (AML). Wugen is also advancing WU-CART-007, an allogeneic CAR-T currently in development for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). For more information, please visit www.wugen.com.
Investor Contact:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
Menu
